Core Viewpoint - Clorox's recent quarterly report revealed disappointing sales and earnings, leading to a decline in stock price and a revised outlook for the fiscal year [2][4][6]. Financial Performance - Clorox reported non-GAAP adjusted earnings per share of $1.45 and sales of $1.67 billion for fiscal Q3, missing analyst estimates by $0.11 per share and falling short of sales expectations by $50 million [4]. - Year-over-year sales decreased by 7.7%, while earnings per share dropped by 15%. Despite an increase in gross margin from 42.2% to 44.6%, it was insufficient to counterbalance the sales decline [5]. Future Guidance - The company now anticipates sales for the fiscal year to be down 1% to flat, a revision from previous guidance of down 1% to up 2%. Organic sales growth is projected to be between 4% and 5%, down from earlier expectations of 4% to 7% [6]. - Clorox maintained its adjusted earnings per share guidance for the year at $6.95 to $7.35, with a likelihood of performance aligning closer to the lower end of this range [7].